An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC. Edward Arrowsmith, MD: We have a couple ways that we're tracking ...
"What has been missing is the patient's perspective," says one industry consultant. The future of clinical pathways is patient-centric: an approach that balances the long-standing focus on ...
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, ...
During the pandemic, the Centers for Medicare & Medicaid Services (CMS) gave Oncology Care Model (OCM) practices the opportunity to "forgo upside and downside risk for performance periods" and floated ...
Steven Peskin, MD, MBA, FACP: We have not embraced clinical pathways in the way that we’re saying that we’re working with a particular third-party clinical pathway company. What we are doing is ...
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) Next-generation sequencing (NGS) is ...
In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, ...
Clinical psychology has long recognized that psychological distress and therapeutic change involve more than cognitive processes alone. Emotion regulation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results